Pyrrolo1,2-bpyridazine spla2 inhibitory
CA 2332528 A1 · Owner: Adachi, Makoto · Inventors: Adachi, Makoto; Ohtani, Mitsuaki; Fukui, Yoshikazu
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Compounds having sPLA2 inhibitory effect represented by general formula (I) prodrugs thereof, pharmaceutically acceptable salts thereof or solvates of the same, and sPLA2 inhibitors containing the same as the active ingredient wherein R1 represents -(L1)-R6 (wherein L1 represents a divalent linking group having 1 to 18 atoms, etc.; and R6 represents a carbon ring having one or more non-interfering substituents, etc.); R2 represents C1-3 alkyl etc.; R3 , represents -(L2)-(acidic group); R4 and R5 represent each hydrogen a non-, interfering substituent, a carbon ring etc.; Xs independently represent each oxygen or sulfur; and RA represents -C(=X)-C(=X)-NH2 etc.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 20, 1999. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended May 20, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 20, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.